Fifth Third Bancorp Grows Position in DaVita Inc. $DVA

Fifth Third Bancorp grew its stake in DaVita Inc. (NYSE:DVA) by 831.4% during the 1st quarter, Holdings Channel reports. The fund owned 38,411 shares of the company’s stock after acquiring an additional 34,287 shares during the period. Fifth Third Bancorp’s holdings in DaVita were worth $5,903,000 at the end of the most recent reporting period.

Other large investors have also made changes to their positions in the company. Nordea Investment Management AB raised its stake in DaVita by 18.0% in the 4th quarter. Nordea Investment Management AB now owns 338,192 shares of the company’s stock valued at $38,321,000 after purchasing an additional 51,607 shares during the last quarter. BI Asset Management Fondsmaeglerselskab A S boosted its stake in shares of DaVita by 63.5% during the 4th quarter. BI Asset Management Fondsmaeglerselskab A S now owns 86,000 shares of the company’s stock worth $9,770,000 after purchasing an additional 33,394 shares during the last quarter. SG Americas Securities LLC grew its holdings in shares of DaVita by 27.4% during the first quarter. SG Americas Securities LLC now owns 212,293 shares of the company’s stock worth $32,627,000 after buying an additional 45,609 shares in the last quarter. M&T Bank Corp raised its position in shares of DaVita by 694.7% in the fourth quarter. M&T Bank Corp now owns 22,307 shares of the company’s stock valued at $2,534,000 after buying an additional 19,500 shares during the last quarter. Finally, Los Angeles Capital Management LLC raised its position in shares of DaVita by 132.2% in the fourth quarter. Los Angeles Capital Management LLC now owns 24,322 shares of the company’s stock valued at $2,888,000 after buying an additional 13,847 shares during the last quarter. Institutional investors and hedge funds own 90.12% of the company’s stock.

DaVita Stock Performance

DVA opened at $233.75 on Friday. DaVita Inc. has a 1 year low of $101.00 and a 1 year high of $239.64. The firm has a 50 day moving average price of $209.17 and a 200 day moving average price of $163.98. The company has a market cap of $15.01 billion, a PE ratio of 21.68, a price-to-earnings-growth ratio of 0.76 and a beta of 0.88.

DaVita (NYSE:DVA) last announced its quarterly earnings results on Tuesday, May 5th. The company reported $2.87 earnings per share for the quarter, beating analysts’ consensus estimates of $2.33 by $0.54. DaVita had a net margin of 5.65% and a negative return on equity of 270.37%. The firm had revenue of $3.42 billion for the quarter, compared to analysts’ expectations of $3.36 billion. During the same period in the previous year, the company posted $2.00 earnings per share. DaVita’s revenue was up 6.0% compared to the same quarter last year. DaVita has set its FY 2026 guidance at 14.100-15.200 EPS. On average, sell-side analysts predict that DaVita Inc. will post 15.07 earnings per share for the current year.

Insider Buying and Selling at DaVita

In related news, CFO Joel Ackerman sold 51,471 shares of the stock in a transaction on Thursday, May 7th. The stock was sold at an average price of $192.10, for a total value of $9,887,579.10. Following the completion of the sale, the chief financial officer directly owned 132,434 shares in the company, valued at approximately $25,440,571.40. This represents a 27.99% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Kathleen Alyce Waters sold 15,405 shares of the firm’s stock in a transaction dated Monday, June 15th. The shares were sold at an average price of $208.40, for a total value of $3,210,402.00. Following the completion of the transaction, the insider directly owned 109,194 shares in the company, valued at $22,756,029.60. This trade represents a 12.36% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders own 1.90% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of brokerages recently issued reports on DVA. Zacks Research lowered shares of DaVita from a “strong-buy” rating to a “hold” rating in a research report on Monday, July 6th. Truist Financial boosted their price target on DaVita from $205.00 to $250.00 and gave the company a “hold” rating in a report on Tuesday. TD Cowen increased their price target on DaVita from $144.00 to $201.00 and gave the stock a “hold” rating in a research note on Monday, May 11th. Weiss Ratings restated a “hold (c+)” rating on shares of DaVita in a report on Monday, June 8th. Finally, Barclays upped their target price on DaVita from $194.00 to $218.00 and gave the company an “equal weight” rating in a research note on Wednesday, July 8th. Two analysts have rated the stock with a Buy rating, five have assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the company presently has an average rating of “Hold” and a consensus target price of $216.50.

About DaVita

DaVita Inc (NYSE: DVA) is a leading provider of kidney care services, specializing in the management and operation of outpatient dialysis centers for patients with chronic kidney failure and end-stage renal disease. Headquartered in Denver, Colorado, the company offers a comprehensive suite of treatment modalities, including in-center hemodialysis, peritoneal dialysis, and home dialysis therapies. In addition to its core dialysis services, DaVita provides patient education, nutritional counseling, vascular access management and related laboratory services to support kidney health and overall patient well-being.

Since its formation in the mid-1990s through a clinical management services spin-off, DaVita has expanded both organically and through strategic partnerships and acquisitions.